OpenAI ex-employees worry about company’s control over their millions of dollars in shares
OpenAI has plans to regularly allow employees to sell some of their equity, but ex-staffers worry they won’t receive equal treatment.
Fed meeting and inflation report both hit Wednesday, and the impact could be huge
A one-two punch starts in the morning with the pivotal consumer price index reading for May, ending with the Fed’s policy meeting in the afternoon
GM trims 2024 EV forecast amid slower-than-expected demand
General Motors is trimming its expected sales and production of all-electric vehicles this year, as U.S. adoption of EVs occurs slower than expected.
‘Put it to rest’: DOJ shoots down House Republican conspiracy that it controlled Trump NY case
‘False…irresponsible’: The Justice Department blasted House Republicans for spreading the false claim the agency was behind the hush money case against Trump.
Live updates: Hunter Biden jury resumes deliberations in gun trial
Hunter Biden faces two federal criminal prosecutions as his father, President Joe Biden, heads for a rematch of the 2020 election against Donald Trump.
Apple execs explain why its AI is different from competitors
Apple officials don’t talk about it as one or multiple models, just “Apple Intelligence.”
GM board approves new $6 billion share buyback authorization
The new buyback authorization comes as a previously announced accelerated $10 billion share repurchase program is expected to be completed this month.
Baltimore key shipping channel fully reopens after Francis Scott Key Bridge collapse
The main shipping channel into the Baltimore port was fully restored for commercial transit, after the March 26 collapse of the Francis Scott Key Bridge.
UAW president under investigation by federal monitor
The monitor accuses UAW leaders of obstructing and interfering with his access to information amid accusations that the union president abused his powers.
FDA advisors recommend Eli Lilly’s Alzheimer’s drug donanemab, paving way for approval
If approved, Eli Lilly’s donanemab would become the second Alzheimer’s drug of its kind currently on the U.S. market after Leqembi from Biogen and Eisai.
